Physician profile
Rose Wood
NPI 1063525681
$6,490.91
in general payments reported to CMS, 2019-2025
21 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,243 · 2020: $156 · 2021: $475 · 2022: $695 · 2023: $661 · 2024: $1,236 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,824.75 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $1,302.47 | 2019-2025 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $763.65 | 2022-2025 | Infuse, Miebo, Infuse Multifocal |
| Tarsus Pharmaceuticals, INC. | $362.24 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $318.49 | 2019-2025 | Total30, Precision 1, Precision7 |
| Johnson & Johnson Vision Care, INC. | $276.63 | 2019-2025 | Acuvue |
| Oyster Point Pharma, INC. | $270.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $233.21 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens, Biofinity Contact Lens |
| Novartis Pharmaceuticals Corporation | $180.25 | 2020-2023 | |
| Sight Sciences, INC. | $162.28 | 2022-2024 | Omni Surgical System |
| Shire North American Group INC | $145.67 | 2019 | |
| Allergan, INC. | $126.25 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2024 | Syfovre |
| Kala Pharmaceuticals, INC. | $99.50 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $71.85 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $60.12 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $49.58 | 2024 | Vevye |
| Dompe US, INC. | $44.19 | 2022-2025 | Oxervate |
| Astellas Pharma US INC | $39.15 | 2024 | Izervay |
| Lumenis, INC | $23.06 | 2021 | |
| Oasis Medical, INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.